Actinium Pharmaceuticals, Inc. (FRA:7AY1)

Germany flag Germany · Delayed Price · Currency is EUR
1.139
+0.036 (3.26%)
At close: Jan 23, 2026
-6.41%
Market Cap30.46M -17.7%
Revenue (ttm)76.71K +11.1%
Net Income-29.49M
EPS-0.95
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume400
Average Volume20
Open1.113
Previous Close1.103
Day's Range1.113 - 1.139
52-Week Range0.998 - 1.821
Betan/a
RSI35.13
Earnings DateMar 30, 2026

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic ... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Sandesh Seth
Employees 25
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 7AY1
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements